Avidity Biosciences, Inc. — Director's Dealing 2025

May 3, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2025-05-01

Reporting Person: Gallagher Kathleen P. (Chief Program Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-01	Common Stock	M	5875	$16.65	Acquired	56429	Direct
2025-05-01	Common Stock	S	5875	$32.3956	Disposed	50554	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-01	Stock Option (Right to Buy)	$16.65	M	5875	Disposed	2032-07-17	Common Stock (5875)	Direct

Footnotes

F1: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.

F2: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.46 to $32.99. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: This option was granted on July 18, 2022 and vests in equal installments of 1/48 of the original number of shares subject to the option on each monthly anniversary of such grant date, until it is fully vested and exercisable on July 18, 2026.